The CIMP-(+) tumors of patients with LOCRC presented moderate tumor differentiation (p = 0.045), MSI status (p = 0.021) and a higher BRAF mutation rate (p = 0.001) (Table 2). The gene discussed is BRAF; the disease is neoplasm.